405 related articles for article (PubMed ID: 22084594)
21. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease.
Bonda DJ; Mailankot M; Stone JG; Garrett MR; Staniszewska M; Castellani RJ; Siedlak SL; Zhu X; Lee HG; Perry G; Nagaraj RH; Smith MA
Redox Rep; 2010; 15(4):161-8. PubMed ID: 20663292
[TBL] [Abstract][Full Text] [Related]
22. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
23. IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.
Huang YS; Ogbechi J; Clanchy FI; Williams RO; Stone TW
Front Immunol; 2020; 11():388. PubMed ID: 32194572
[TBL] [Abstract][Full Text] [Related]
24. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease.
Whiley L; Chappell KE; D'Hondt E; Lewis MR; Jiménez B; Snowden SG; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Swann JR; Hye A; Lovestone S; Legido-Quigley C; Holmes E;
Alzheimers Res Ther; 2021 Jan; 13(1):20. PubMed ID: 33422142
[TBL] [Abstract][Full Text] [Related]
25. Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease.
Boros FA; Vécsei L
Expert Opin Ther Targets; 2021 Oct; 25(10):877-888. PubMed ID: 34720020
[TBL] [Abstract][Full Text] [Related]
26. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
[TBL] [Abstract][Full Text] [Related]
27. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
Donley DW; Realing M; Gigley JP; Fox JH
PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
[TBL] [Abstract][Full Text] [Related]
28. Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.
Sharma VK; Singh TG; Prabhakar NK; Mannan A
Neurochem Res; 2022 Jun; 47(6):1459-1476. PubMed ID: 35133568
[TBL] [Abstract][Full Text] [Related]
29. Investigation of the kynurenine pathway in Indoleamine 2, 3 dioxygenase deficient mice with inflammatory arthritis.
Kolodziej L
Transgenic Res; 2013 Oct; 22(5):1049-54. PubMed ID: 23417792
[TBL] [Abstract][Full Text] [Related]
30. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.
Fatokun AA; Hunt NH; Ball HJ
Amino Acids; 2013 Dec; 45(6):1319-29. PubMed ID: 24105077
[TBL] [Abstract][Full Text] [Related]
31. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.
Larkin PB; Sathyasaikumar KV; Notarangelo FM; Funakoshi H; Nakamura T; Schwarcz R; Muchowski PJ
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2345-2354. PubMed ID: 27392942
[TBL] [Abstract][Full Text] [Related]
32. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Dounay AB; Tuttle JB; Verhoest PR
J Med Chem; 2015 Nov; 58(22):8762-82. PubMed ID: 26207924
[TBL] [Abstract][Full Text] [Related]
33. The kynurenine pathway in stem cell biology.
Jones SP; Guillemin GJ; Brew BJ
Int J Tryptophan Res; 2013 Sep; 6():57-66. PubMed ID: 24092986
[TBL] [Abstract][Full Text] [Related]
34. Indoleamine-2,3-dioxygenase mediates neurobehavioral alterations induced by an intracerebroventricular injection of amyloid-β1-42 peptide in mice.
Souza LC; Jesse CR; Antunes MS; Ruff JR; de Oliveira Espinosa D; Gomes NS; Donato F; Giacomeli R; Boeira SP
Brain Behav Immun; 2016 Aug; 56():363-77. PubMed ID: 26965653
[TBL] [Abstract][Full Text] [Related]
35. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease.
Forrest CM; Mackay GM; Stoy N; Spiden SL; Taylor R; Stone TW; Darlington LG
J Neurochem; 2010 Jan; 112(1):112-22. PubMed ID: 19845828
[TBL] [Abstract][Full Text] [Related]
36. Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
Stoy N; Mackay GM; Forrest CM; Christofides J; Egerton M; Stone TW; Darlington LG
J Neurochem; 2005 May; 93(3):611-23. PubMed ID: 15836620
[TBL] [Abstract][Full Text] [Related]
37. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN
J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232
[TBL] [Abstract][Full Text] [Related]
38. Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease.
Chen LM; Bao CH; Wu Y; Liang SH; Wang D; Wu LY; Huang Y; Liu HR; Wu HG
J Neuroinflammation; 2021 Jun; 18(1):135. PubMed ID: 34127024
[TBL] [Abstract][Full Text] [Related]
39. The kynurenine pathway implicated in patient delirium: possible indications for indoleamine 2,3 dioxygenase inhibitors.
Heimberger AB; Lukas RV
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647830
[TBL] [Abstract][Full Text] [Related]
40. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis.
Changsirivathanathamrong D; Wang Y; Rajbhandari D; Maghzal GJ; Mak WM; Woolfe C; Duflou J; Gebski V; dos Remedios CG; Celermajer DS; Stocker R
Crit Care Med; 2011 Dec; 39(12):2678-83. PubMed ID: 21765346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
